ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RAPP vs AMPH // 10Y YIELD & FRED MACRO BETA

Rapport Therapeutics Inc. (NASDAQ) VS. Amphastar Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: RAPP 1 — AMPH 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RAPP VS. AMPH) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RAPP AMPH SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 49.50% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -22.90% 9.00% -31.90 AMPH /roic <GO>
EV/EBITDA & P/E Valuation — 9.4x — TIE /valuation <GO>
Free Cash Flow Yield -7.58% 10.58% -18.16 AMPH /fcf-yield <GO>
Operating Margin — 19.50% — TIE /operating-margins <GO>
Net Profit Margin — 13.60% — TIE /net-margins <GO>
Revenue Growth (YoY) — -1.70% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 2.47 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 7/9 -5.00 AMPH /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 37.5 66.8 -29.29 AMPH /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 10.9x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.16B $1.15B $16.0M RAPP /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RAPP REV AMPH REV RAPP GROSS % AMPH GROSS % RAPP FCF AMPH FCF
FY 2025 $0 $719.9M — 49.5% -$88.1M $121.2M
FY 2024 $0 $732.0M — 51.1% -$67.2M $172.3M
FY 2023 $0 $644.4M — — -$27.2M $183.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RAPP // BETA —
AMPH // BETA —